CD8A and neoplasm: For some time, our group has been developing vaccination strategies capable of stimulating and expanding substantial numbers of tumor-reactive T cells and recently we were successful with a peptide vaccine where 20-60 % of total CD8 T cells were shown to be antigen specific and capable of limiting tumor growth in mice.